OC
CNCR

Oppenheimer & Co’s ETF Series Solutions Trust Range Cancer Therapeutics ETF CNCR Stock Holding History

Oppenheimer & Co’s Portfolio CNCR Stock Details CNCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,213
Closed -$215K – 1318
2019
Q1 		$215K Sell
10,213
-14
-0.1% -$294 0.01% 1190
2018
Q4 		$193K Buy
10,227
+2,120
+26% +$44.2K 0.01% 1112
2018
Q3 		$201K Buy
+8,107
New +$199K 0.01% 1228

Other funds holding CNCR

BL
BCWM LLC Overland Park, Kansas $353M AUM 20.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
SG
StoneX Group New York $1.86B AUM 21.3% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Oppenheimer & Co's CNCR Position: Q2 2019 in Review

Oppenheimer & Co sold out of ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) in Q2 2019, closing a stake of 10,213 shares — an estimated $215K sold.

Oppenheimer & Co first reported a position in CNCR in Q3 2018 and held it in 3 quarters. The position peaked at $215K in Q1 2019. 20 funds tracked by Wall St. Rank hold CNCR as of Q2 2019.

  • Oppenheimer & Co reported no remaining ETF Series Solutions Trust Range Cancer Therapeutics ETF position as of Q2 2019 after selling out during the quarter.
  • Oppenheimer & Co sold 10,213 ETF Series Solutions Trust Range Cancer Therapeutics ETF shares in Q2 2019, an estimated $215K.
  • Oppenheimer & Co first reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF in Q3 2018 and held it in 3 quarters.
  • Oppenheimer & Co's ETF Series Solutions Trust Range Cancer Therapeutics ETF position peaked at $215K in Q1 2019.
  • 20 funds tracked by Wall St. Rank held ETF Series Solutions Trust Range Cancer Therapeutics ETF as of Q2 2019.

Based on Oppenheimer & Co's 13F filing for Q2 2019, filed 9 Aug 2019.